Condition: Rectal Cancer Stage III · Sponsor: Zhejiang Cancer Hospital
To explore whether the application of irinotecan under the guidance of UGT1A1 gene in neoadjuvant chemotherapy and radiotherapy for locally advanced rectal cancer could improve the clinical efficacy in the real world.
This description comes directly from the study's public registry record.
Ji Zhu, MD · 571-88128142 · leo.zhu@126.com
Quanquan Sun, MD · 571-88128142 · sunqq@zjcc.org.cn
Always discuss trial participation with your own doctor first.
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05148767